Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01885195 · ClinicalTrials.gov registry record · Phase 2

MEK162 for Patients With RAS/RAF/MEK Activated Tumors

A Phase 2 study of Solid Tumor and Hematologic Malignancies, sponsored by Pfizer.

Completed
Registry status
Phase 2
Development phase
110
Enrollment target
20
Study locations

NCT01885195: Completed Phase 2 study of Solid Tumor and Hematologic Malignancies, sponsored by Pfizer.

NCT01885195 is a Phase 2 study of Solid Tumor and Hematologic Malignancies that has completed, run by Pfizer. The registered enrollment target is 110 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (17% lower). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01885195, a Phase 2 study of Solid Tumor and Hematologic Malignancies, has completed, sponsored by Pfizer.

COMPLETED
Registry status
Phase 2
Development phase
110 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this signal seeking study is to determine whether treatment with MEK162 demonstrates sufficient efficacy in select pathway-activated solid tumors and/or hematologic malignancies to warrant further study

Primary Outcome

CBR: participants with complete response (CR), partial response (PR) or stable disease (SD) for at least 16 weeks. As per RECIST 1.1, CR: disappearance of all target and non-target lesions, normalization of tumor marker level, pathological lymph nodes assigned as target or non-target lesions must have a reduction in short axis to less than (\<) 10 millimeter (mm); PR: at least a 30 percent (%) decrease in sum of diameter of all target lesions, taking as reference the baseline sum of diameters; S

Conditions Studied

Solid Tumor and Hematologic Malignancies

Interventions

  • DRUG MEK162

Study Locations (20)

Florida

  • Florida Cancer Specialists Florida Cancer Specialists (31 - Fort Myers
  • Memorial Cancer Institute Memorial Healthcare System - Hollywood
  • Cancer Specialists of North Florida - Jacksonville
  • Mt. Sinai Comprehensive Cancer Center - Miami Beach
  • Ocala Oncology Center Dept. of Ocala Oncology Center - Ocala
  • Cancer Centers of Florida PA Cancer Centers of FL-Orlando-4 - Ocoee

Connecticut

  • Yale University School of Medicine Yale Cancer Center - New Haven
  • Whittingham Cancer Center Norwalk Hospital - Norwalk
  • Eastern Connecticut Hematology & Oncology Associates Dept. of ECHO - Norwich
  • Hematology Oncology PC Stamford Hospital - Stamford

Arizona

  • Arizona Oncology Associates AZ Oncology Assoc. - Phoenix
  • Arizona Oncology Associates HOPE Division - Phoenix
  • Arizona Oncology Associates PC- NAHOA - Sedona

California

  • PCR Oncology - Pismo Beach
  • University of California Davis Cancer Center UC Davis Cancer (3) - Sacramento

Alabama

  • University of South Alabama / Mitchell Cancer Institute Univ South Alabama - Mobile

Alaska

  • Alaska Oncology and Hematology AOH (2) - Anchorage

Arkansas

  • Highlands Oncology Group Highlands Oncology Group (22) - Fayetteville

Colorado

  • Rocky Mountain Cancer Centers USOR - Boulder

Trial Details

FieldValue
Enrollment Target 110 participants
Start Date 2013-10-10
Est. Completion 2017-04-11
Phase Phase 2
Pfizer

1,845 total trials

What the finished NCT01885195 record still lists

NCT01885195 is an interventional study that assigns participants to a tested intervention. The registered 110 participants enrollment target is mid-sized for trials with a published cap, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (17% lower).

The record links to 1 condition, with Solid Tumor and Hematologic Malignancies appearing as the primary indexed condition, and to 1 intervention - of which MEK162 is the first listed.

NCT01885195 names 20 study sites across 9 states, led by Florida, Connecticut, Arizona.

Frequently Asked Questions

What is clinical trial NCT01885195 about?

NCT01885195 is a clinical study titled "MEK162 for Patients With RAS/RAF/MEK Activated Tumors". The purpose of this signal seeking study is to determine whether treatment with MEK162 demonstrates sufficient efficacy in select pathway-activated solid tumors and/or hematologic malignancies to warrant further study

What is the current status of trial NCT01885195?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 110 participants. The study started on 2013-10-10. Estimated completion is 2017-04-11.

What conditions does trial NCT01885195 study?

This clinical trial studies the following conditions: Solid Tumor and Hematologic Malignancies.

What interventions are being tested in trial NCT01885195?

The interventions under investigation include: MEK162 (DRUG).

Who is sponsoring clinical trial NCT01885195?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01885195 being conducted?

This trial has 20 study locations across Alabama, Alaska, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

How this trial's enrollment target compares

Where NCT01885195's enrollment target sits among peer trials

110 632nd of 2000 higher than 1,361 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01530373 · 110 participants · Phase 2

    Solifenacin Compared to Clonidine for Reducing Hot Flashes Among Breast Cancer Patients

  • NCT02379377 · 110 participants · Phase 1

    18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant

  • NCT02411773 · 110 participants · Phase 1

    Sympatholysis in Chronic Kidney Disease

  • NCT03190941 · 110 participants · Phase 1

    Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT01885195, the US trial registry maintained by the National Library of Medicine. NCT01885195 (mid enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.